Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 4/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135930 | 0.94 | C5AR1 (0.36) | BCHEHTR1AHTR2CHTR2BMEN1 | |
| SCHEMBL5136565 | 0.93 | BCL2L2 (0.36) | BCHEHTR1AHTR2CHTR2BMEN1 | |
| SCHEMBL5137492 | 0.89 | C5AR1 (0.42) | HDAC1MEN1KMT2ACRHR1C5AR1 | |
| SCHEMBL5136819 | 0.88 | TSPO (0.40) | HDAC1BCHEMEN1KMT2ACRHR1 | |
| SCHEMBL4770190 | 0.87 | TLR7 (0.38) | HDAC1MEN1KMT2ACRHR1C5AR1 | |
| SCHEMBL5135487 | 0.87 | BCHE (0.38) | HDAC1BCHEHTR1AHTR2CHTR2B | |
| SCHEMBL5074977 | 0.86 | C5AR1 (0.39) | HDAC1BCHECRHR1C5AR1 | |
| SCHEMBL5074785 | 0.86 | C5AR1 (0.40) | HDAC1CRHR1C5AR1 | |
| SCHEMBL5135323 | 0.82 | C5AR1 (0.39) | HDAC1MEN1KMT2ACRHR1C5AR1 | |
| SCHEMBL5135924 | 0.82 | ESR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |